Novel trifluoroacetophenone derivatives as malonyl-CoA decarboxylase inhibitors
摘要:
A series of trifluoroacetophenone derivatives were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Some of the 'reverse amide' analogs were found to be potent inhibitors of MCD enzyme activity. The trifluoroacetyl group may interact with the MCD active site as the hydrate in a similar fashion to the hexafluoroisopropanol analogs reported previously. Adding electron-withdrawing groups to the phenyl ring stabilizes the hydrated species and enhances this interaction. (c) 2006 Elsevier Ltd. All rights reserved.
Novel trifluoroacetophenone derivatives as malonyl-CoA decarboxylase inhibitors
摘要:
A series of trifluoroacetophenone derivatives were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Some of the 'reverse amide' analogs were found to be potent inhibitors of MCD enzyme activity. The trifluoroacetyl group may interact with the MCD active site as the hydrate in a similar fashion to the hexafluoroisopropanol analogs reported previously. Adding electron-withdrawing groups to the phenyl ring stabilizes the hydrated species and enhances this interaction. (c) 2006 Elsevier Ltd. All rights reserved.
Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
申请人:——
公开号:US20040063671A1
公开(公告)日:2004-04-01
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
1
Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators
申请人:Arrhenius Thomas
公开号:US20080070869A1
公开(公告)日:2008-03-20
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.
MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS
申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
公开号:EP1377290B1
公开(公告)日:2006-10-04
US7279477B2
申请人:——
公开号:US7279477B2
公开(公告)日:2007-10-09
Novel trifluoroacetophenone derivatives as malonyl-CoA decarboxylase inhibitors
作者:David M. Wallace、Masayuki Haramura、Jie-Fei Cheng、Thomas Arrhenius、Alex M. Nadzan
DOI:10.1016/j.bmcl.2006.09.023
日期:2007.2
A series of trifluoroacetophenone derivatives were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Some of the 'reverse amide' analogs were found to be potent inhibitors of MCD enzyme activity. The trifluoroacetyl group may interact with the MCD active site as the hydrate in a similar fashion to the hexafluoroisopropanol analogs reported previously. Adding electron-withdrawing groups to the phenyl ring stabilizes the hydrated species and enhances this interaction. (c) 2006 Elsevier Ltd. All rights reserved.